G. Leonard Baker Jr., Director at CORCEPT THERAPEUTICS INC (CORT), bought 200,000 shares at $33.00 ($6.6M) on 2026-03-17, disclosed to the SEC on 2026-03-19.
Director G. Leonard Baker Jr. purchased $2.5M worth of stock, marking the largest purchase in the company's history. This significant insider buying coincides with the stock trading near its 52-week low after a 59% decline over the last 90 days.
CORT is currently trading at $34.08, down 59.31% over the last 90 days and 41.24% over the past year. The stock is currently 18.91% above its 52-week low of $28.66.
The company announced it will resubmit its new drug application for the Cushing's Syndrome drug in the coming weeks following positive FDA talks (Stocktwits, May 27, 2026). Additionally, this $2.5M purchase represents the largest insider purchase in the company's history, signaling potential bottom-fishing.
The stock carries a high short interest of 12.88%, which could lead to volatility if the NDA resubmission fails. Furthermore, the stock trades at a high P/E ratio of 190.43, making it vulnerable to multiple compression if growth slows.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.00 | 75,782 | $2.5M | 37.7% |
| 2 | $33.00 | 75,782 | $2.5M | 37.7% |
| 3 | $33.56 | 24,218 | $813K | 12.3% |
| 4 | $33.56 | 24,218 | $813K | 12.3% |
| Total | $33.14 avg | 200,000 | $6.6M | 100% |
| Filing → |
| CORT | BUY | 2020-11-30 | $8K | — | Filing → |
| CORT | BUY | 2020-11-24 | $68K | — | Filing → |
| CORT | BUY | 2020-11-19 | $42K | — | Filing → |